SEC Form S-4 filed by Coeptis Therapeutics Holdings Inc.
$COEP
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Unavailable
Unavailable
Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.
4 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Issuer)
4 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Issuer)
4 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Issuer)
WEXFORD, Pa., June 26, 2025 (GLOBE NEWSWIRE) -- Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) ("Coeptis" or the "Company"), a next-gen technology and biopharmaceutical company, is pleased to announce the filing of a registration statement on Form S-4 with the Securities and Exchange Commission ("SEC") related to the Company's previously announced and proposed definitive merger agreement (the "Merger") with Z Squared Inc. ("Z Squared"). The Form S-4 includes a preliminary proxy statement/prospectus regarding the proposed transaction. The registration statement has not yet become effective, and the information contained therein is subject to change. About Coeptis Therapeutics Hold
WEXFORD, Pa. and PRINCETON, N.J., May 28, 2025 (GLOBE NEWSWIRE) -- SNAP Biosciences, Inc a majority-owned subsidiary of Coeptis Therapeutics Holdings Inc. (NASDAQ:COEP) and Monarch Therapeutics Inc., a biotechnology company pioneering next-generation immunotherapies, today announced a licensing agreement to enable the development and commercialization of SNAP Biosciences' proprietary Snap-Car NK cell therapy platform in oncology using Monarch's small molecule adaptor technology. This agreement grants SNAP Biosciences access to Monarch's novel small-molecule adaptor-based technology platform, significantly broadening the functionality of the Snap-Car universal CAR-based receptor platform.
NUBURU Poised to Finalize Strategic Acquisition and Prepare the Adoption of Advanced Technology, Artificial Intelligence & Robotics Initiatives as It Awaits Italian Government ‘Golden Power' Approval NUBURU, Inc. (NYSE:BURU), a leader in high-power blue laser technology, announced today that it has filed with the Securities and Exchange Commission a Form S-3 Registration statement for $100 million. This strategic move is designed to provide the company with the necessary capital to facilitate the ongoing acquisition plan and successfully relaunch its Blue Laser technology business unit. As reaffirmed in the latest communications, NUBURU aims at completing the purchase of defense and secur
Coeptis bolsters pipeline with two Phase 1 clinical stage assets leveraging NK cell therapies in relapsed or refractory acute myeloid leukemia (AML)/high risk MDS and hospitalized respiratory infections, as well as preclinical programs for hematologic and solid tumors WEXFORD, Pa., Aug. 17, 2023 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, announced that it has completed the exclusive license of key assets from Deverra Therapeutics Inc. ("Deverra") related to its proprietary allogeneic stem cell expansion and directed differentiation platform for the generat
Dr. Delaney joins Coeptis after securing exclusive rights from Deverra Therapeutics for its allogeneic immuno-oncology platform and clinical stage programs WEXFORD, Pa., Aug. 30, 2023 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, announced that Colleen Delaney, MD, MSc, has been appointed Chief Scientific and Medical Officer of Coeptis following the completion of an exclusive rights agreement with Deverra Therapeutics for its allogeneic immuno-oncology platform and clinical stage programs.
15-year accounting and finance career spans several sectors including life sciences and underscores financial leadership abilities WEXFORD, Pa., May 17, 2023 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) ("Coeptis" or the "Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, announced today the appointment of Brian Cogley, MBA, to the position of Chief Financial Officer (CFO) effective immediately. Mr. Cogley brings 15 years of accounting and finance experience to Coeptis, having previously held positions of increasing authority at two "Big 4" accounting firms and served on the management teams of multiple companies in diverse in
S-4 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Filer)
10-K/A - Coeptis Therapeutics Holdings, Inc. (0001759186) (Filer)
424B3 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Filer)
SC 13G/A - Coeptis Therapeutics Holdings, Inc. (0001759186) (Subject)